Company
Exhalation
Delivery Systems
Therapeutic
Areas
Products
- XHANCE^®
- ONZETRA^® Xsail^®
Research &
Development
- XHANCE^®– Future Development
- Partnerships
Investors
News &
Media
Scientific
Communications
- Peer-Reviewed Journal Publications

AVP-825

December 22, 2014

Approved for migraine treatment (licensed to Avanir Pharmaceuticals, Inc., an affiliate of Otsuka Pharmaceutical Co., Ltd.).

Contact Us
P.O. Terms & Conditions
Join Our Team
Privacy Policy
Terms of Use
Site Map

©2018 OptiNose US, Inc. OPTINOSE-17-013b 10/2017

Accessibility Tools

Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset